Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth in most patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at a major international cancer conference.
uncertain
Pairing → pair → conference
The findings, shared at the EORTC-NCI-AACR Symposium in Barcelona, come from a phase 1/2 trial testing a daily oral medication called daraxonrasib, along with two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel.
asserted
findings → share → drugs
The trial focused on 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.
asserted
who → focus → disease
Pancreatic cancer is notoriously difficult to treat, because more than half of patients are diagnosed after the disease has already spread, research shows.
asserted
research → treat → patients
In major clinical trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumors in about 23% to 42% of patients, but the disease typically begins growing again after five to six months, and most patients survive between eight and 11 months.
asserted
patients → shrink → months
According to National Cancer Institute data, only about 3% of patients with distant-stage disease live five years past diagnosis.
uncertain
% → accord → diagnosis
In the new study, which tracked patients for a median follow-up of 18 months, tumors shrank in 60.7% of cases, including 8.2% where they disappeared entirely on scans.
asserted
they → track → scans
Overall, the combination stopped tumor growth in 90.2% of participants.
asserted
combination → stop → participants
Patients went a median of 12.8 months before their cancer worsened, almost double the timeframe typically seen with standard chemotherapy, and 76.6% were still alive at the one-year mark, the study found.
"
asserted
study → go → mark
We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year," said study lead Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, in a press release.
asserted
Park → see → release
More than 90% of pancreatic cancers are driven by a faulty gene called RAS, which allows tumors to keep growing.
asserted
tumors → drive → gene
Daraxonrasib is designed to turn off that growth signal, something scientists long thought was impossible to fix with medication.
asserted
scientists → design → medication
Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, who was not involved in the research, said the results show that RAS-targeted drugs can be combined with existing treatments at the start of treatment to potentially achieve longer-lasting benefits.
asserted
drugs → involve → benefits
Side effects included rash, diarrhea, fatigue and low blood cell counts linked to chemotherapy, most of which were manageable with standard care.
asserted
most → include → care
Only 5% of patients stopped treatment because of side effects tied to daraxonrasib.
asserted
% → stop → daraxonrasib
Researchers emphasized that the findings carry some limitations.
asserted
findings → emphasize → limitations
Because this was an early-phase, single-group study involving 61 people, all participants received the experimental combination.
asserted
participants → involve → combination
Without a direct comparison group of patients receiving standard chemotherapy alone, doctors cannot yet confirm how much better the new regimen performs or whether it definitively extends overall survival.
asserted
it → receive → survival
The findings also apply strictly to metastatic pancreatic cancer, even though RAS mutations drive several other cancers, including certain lung, colorectal and gynecological cancers.
asserted
mutations → apply → cancers
Separate studies would be needed to test whether the combination works in those diseases.
asserted
combination → need → diseases
The trial was funded by Revolution Medicines, the California-based developer of daraxonrasib.
asserted
trial → fund → daraxonrasib
To determine whether these early findings translate into a durable survival benefit, researchers have launched a larger, randomized phase 3 trial, called RASolute-303, which directly compares daraxonrasib — both on its own and combined with chemotherapy — against standard chemotherapy alone.
asserted
which → determine → chemotherapy